Dr. Maurice Treacy serves as an ARCH Venture Partner in Dublin, Ireland. Dr. Treacy has over 20 years of executive leadership experience in the biotech/pharma sector.
He is a founder and VP, Strategic Alliances at Genomics Medicine Ireland, an ARCH portfolio company. Dr. Treacy participated in securing global marketed approval of three therapeutic products while with Merck Serono and identified genetically validated targets while at Pfizer. As Director of LifeScieces at SFI (Science Foundation Ireland) and CEO of NIBRT (National Institute for Bioprocess Research & Training), he helped build the Irish research eco-system. He also served as CEO and founder of HiberGen, a start-up genomics-based drug development company. Dr. Treacy has extensive published research papers and is a co-inventor on over 80 U.S. patent applications.
Dr. Treacy was awarded a Ph.D. in Pharmacology from University College Dublin (UCD) and completed post-doctoral work at the University of California, San Diego. He holds an MBA from Northeastern University Boston, is an Adjunct Professor at the UCD Smuffit Business School, and is a member of the UCD Governing Authority.